SEngine Precision Medicine’s proprietary approach, known as the PARIS® Test, aids in identifying effective and less toxic therapies available for patients with solid cancer tumors. The PARIS® Test starts with a live tissue sample from a patient's unique tumor extracted during a biopsy. SEngine Precision Medicine scientists receive the live tumor biopsy at its CLIA certified lab in Seattle. The PARIS® Test utilizes hundreds of 3D organoids grown by SEngine Precision Medicine scientists from the patient's unique cancer. The 3D organoids are tested against up to 140 cancer fighting drugs and drug combinations.
Save the Tumor. Spare the Patient
The patient's oncologist receives test results within two to six weeks. The PARIS Report is a comprehensive analysis and deep understanding of how an individual’s cancer cells respond to therapies. The SPM Score ranks all therapies based on their response and assists the oncologist and the medical team in outlining a personalized treatment strategy.
→ First and only lab in the United States to earn Clinical Laboratory Improvement Amendments (CLIA) certification for a high throughput, high complexity test for all solid tumors. Guided by experienced lab director Shalini Pereira, PhD.
→ SEngine Precision Medicine’s Compassionate Use Case Coordinator can assist patients and oncologists with paperwork associated with documentation for N-of-1 clinical trials.
→ See live tumor collection guidelines and published research.
Resources for Patients + Oncologist
The test is private and secure and is available in the U.S. (New York state pending)
PARIS® Test is currently not covered by most insurance companies. Fees apply. See Pre-screen Form for details.